ALK and diffuse large B-cell lymphoma: CODOX-M/IVAC (cyclophosphamide, vincristine, doxorubicin, methotrexate alternating with ifosfamide, etoposide, cytarabine), dose-adjusted EPOCH and HyperCVAD (cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with HD-MTX and cytarabine) are the suggested therapies.[4] Novel agents such as proteasome inhibitor bortezomib for PBL,[31] brentuximab for PEL,[32] anti-interleukin-6 monoclonal antibody siltuximab for MCD[33] and crizotinib for ALK+ DLBCL[34] might be promising.